ArticlePloS one2018
Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- In silico analysis of patient specific coagulation and flow effects on fibrin clot formation.Scientific reports · 2026Article
- GATA Transcription Factors: A Cross-Road for Erythropoiesis, Neurodevelopment, and Synucleinopathies.Developmental neurobiology · 2025Review
- Fibrinography and thrombography (thrombodynamics-4D) in atrial fibrillation assessment of direct oral anticoagulants in geriatrics patients aged 80 years and older receiving direct oral anticoagulant therapy.Research and practice in thrombosis and haemostasis · 2025Article
- Comparison of standard and global hemostasis assays in cord and peripheral blood of newborns.Pediatric research · 2025Article
- Severely Ill COVID-19 Patients May Exhibit Hypercoagulability Despite Escalated Anticoagulation.Journal of clinical medicine · 2025Article
- Targeted Blood Plasma Proteomics and Hemostasis Assessment of Post COVID-19 Patients with Acute Myocardial Infarction.International journal of molecular sciences · 2023Article
- Integral assays of hemostasis in hospitalized patients with COVID-19 on admission and during heparin thromboprophylaxis.PloS one · 2023Article
- Systems Biology Approach for Personalized Hemostasis Correction.Journal of personalized medicine · 2022Article
- Circulating Cytokines in Myocardial Infarction Are Associated With Coronary Blood Flow.Frontiers in immunology · 2022Article
- Clinical use of thrombin generation assays.Journal of thrombosis and haemostasis : JTH · 2021Review
- Hypercoagulation detected by routine and global laboratory hemostasis assays in patients with infective endocarditis.PloS one · 2021Observational
- Features of Blood Clotting on Thromboelastography in Hospitalized Patients With Cirrhosis.The American journal of medicine · 2020Article
- Article
- An enhanced clot growth rate before in vitro fertilization decreases the probability of pregnancy.PloS one · 2019Observational
- Correction of Anticoagulant Therapy in Patients with Severe COVID-19 Virus Infection Using a Thrombodynamics Coagulation Assay.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeparin therapy and prophylaxis may be accompanied by bleeding and thrombotic complications due to individual responses to treatment. Dosage control based on standard laboratory assays poorly reflects the effect of the therapy. The aim of our work was to compare the heparin sensitivity of new thrombodynamics (TD) assay with sensitivity of other standard and global coagulation tests available to date. STUDY POPULATION AND
methodsA total of 296 patients with high risk of venous thromboembolism (deep vein thrombosis (DVT), early postoperative period, hemoblastosis) were enrolled in the study. We used a case-crossover design to evaluate the sensitivity of new thrombodynamics assay (TD) to the hemostatic state before and after unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) therapy/prophylaxis and to compare it with the activated partial thromboplastin time (APTT), anti-Xa activity test, thrombin generation test (TGT) and thromboelastography (TEG). A receiver operating characteristic (ROC) curve analysis was used to evaluate changes before and after heparin prophylaxis and therapy. Blood was sampled before heparin injection, at the time of maximal blood heparin concentration and before the next injection.
resultsHypercoagulation before the start of heparin treatment was detected by TD, TGT and TEG but not by APTT. The area under the ROC curve (AUC) was maximal for TD and anti-Xa, intermediate for TGT and TEG and minimal for APTT.
conclusionsThese results indicate that TD has a high sensitivity to the effects of UFH and LMWH after both prophylactic and therapeutic regimes and may be used for heparin monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.